Bicara Therapeutics/$BCAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bicara Therapeutics
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Ticker
$BCAX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
55
ISIN
US0554771032
Website
BCAX Metrics
BasicAdvanced
$514M
-
-$3.05
-
-
Price and volume
Market cap
$514M
52-week high
$28.09
52-week low
$7.80
Average daily volume
1.1M
Financial strength
Current ratio
24.621
Quick ratio
24.167
Total debt to equity
0.129
Profitability
EBITDA (TTM)
-108.741
Effective tax rate (TTM)
-0.28%
Management effectiveness
Return on equity (TTM)
-27.26%
Valuation
Price to book
1.12
Price to tangible book (TTM)
1.12
Price to free cash flow (TTM)
-3.23
Free cash flow yield (TTM)
-30.96%
Free cash flow per share (TTM)
-291.98%
Growth
Earnings per share change (TTM)
-96.69%
Bulls say / Bears say
Wedbush initiated coverage of Bicara Therapeutics with an 'Outperform' rating and a $31.00 price target, indicating strong confidence in the company's growth potential. (defenseworld.net)
Bicara Therapeutics successfully closed its initial public offering, raising approximately $362 million, providing substantial capital to advance its research and development efforts. (stocktitan.net)
The global market for head and neck cancer therapeutics is projected to grow at a CAGR of 11.8% from 2024 to 2030, potentially benefiting Bicara's focus in this area. (seekingalpha.com)
Wells Fargo & Company initiated coverage on Bicara Therapeutics with an 'Underweight' rating and an $8.00 price target, suggesting potential downside risk. (americanbankingnews.com)
Bicara reported a significant revenue decline in 2024, with revenue decreasing by approximately 94.4% compared to 2023, indicating potential operational challenges. (ainvest.com)
The company reported a quarterly loss of $0.39 per share, missing analysts' consensus estimates of ($0.31), which may raise concerns about its financial performance. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
BCAX News
AllArticlesVideos
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·2 weeks ago
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
GlobeNewsWire·3 weeks ago
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bicara Therapeutics stock?
Bicara Therapeutics (BCAX) has a market cap of $514M as of June 21, 2025.
What is the P/E ratio for Bicara Therapeutics stock?
The price to earnings (P/E) ratio for Bicara Therapeutics (BCAX) stock is 0 as of June 21, 2025.
Does Bicara Therapeutics stock pay dividends?
No, Bicara Therapeutics (BCAX) stock does not pay dividends to its shareholders as of June 21, 2025.
When is the next Bicara Therapeutics dividend payment date?
Bicara Therapeutics (BCAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Bicara Therapeutics?
Bicara Therapeutics (BCAX) does not currently have a Beta indicator.